Drug (brand name) | Sponsor | Properties | Indication | Approval date | Review |
---|---|---|---|---|---|
Vemurafenib (Zelboraf) | Roche | BRAF inhibitor | BRAF-positive unresectable or metastatic melanoma | 08/17/2011 | P, O |
Dabrafenib mesylate (Tafinlar) | Novartis | Kinase inhibitor with activity against BRAFV600E/D/K, wild-type BRAF and other kinases | Unresectable or metastatic melanoma with BRAFV600E mutation | 05/29/2013 | S, O |
Encorafenib (Braftovi) | Array BioPharma | BRAF inhibitor | BRAF-mutated melanoma | 06/27/2018 | S, O |
Trametinib DMSO (Mekinist) | Novartis | MEK1/2 inhibitor | Unresectable or metastatic melanoma with BRAFV600E mutation | 05/29/2013 | S, O |
Cobimetinib fumarate (Cotellic) | Genentech | MEK inhibitor | Melanoma with BRAFV600E/K mutations | 11/10/2015 | P, O |
Binimetinib (Mektovi) | Array BioPharma | MEK inhibitor | BRAF-mutated melanoma | 06/27/2018 | S, O |
Ipilimumab (Yervoy) | Bristol-Myers Squibb | CTLA4‑directed mAb | Unresectable or metastatic melanoma | 03/25/2011 | P, O |
Pembrolizumab (Keytruda) | Merck | PD1-directed mAb | Metastatic melanoma | 09/04/2014 | P, O |
Nivolumab (Opdivo) | Bristol-Myers Squibb | PD1-directed mAb | Unresectable or metastatic melanoma | 12/22/2014 | P, O |
Vismodegib (Erivedge) | Genentech | Smoothened inhibitor | Advanced basal cell carcinoma | 01/30/2012 | P |
Sonidegib phosphate (Odomzo) | Sun Pharma | Smoothened inhibitor | Basal cell carcinoma | 07/24/2015 | S |
Avelumab (Bavencio) | Emd Serono | PDL1-directed mAb | Merkel cell carcinoma | 03/23/2017 | P, O |
Cemiplimab (Libtayo) | Regeneron | PD1-directed mAb | Cutaneous squamous cell carcinoma | 09/28/2018 | P |